Cannabigerol Market Outlook, Trends & Forecast 2033

Cannabigerol by Application (Edibles, Vapes, Pharmaceuticals, Cosmetics), by Types (CBG Distillate, CBG lsolate), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Cannabigerol Market Size | CAGR 22.5 Forecast 2033

Cannabigerol Market Outlook, Trends & Forecast 2033

🏭 Chemicals & Materials🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cannabigerol Market Overview

Cannabigerol (CBG) is a non‑psychoactive cannabinoid found in the Cannabis plant that serves as a biochemical precursor to THC, CBD and other cannabinoids. Cannabigerol market size is gaining prominence as consumers and manufacturers seek therapeutic alternatives with minimal side effects. The growth outlook reflects a robust market forecast driven by expanding product portfolios and regulatory liberalization, positioning the industry for significant expansion across health, wellness and consumer goods segments. According to recent industry analyses, the global CBG market was valued at approximately $300 million in 2025, with expectations to exceed $1 billion by 2033.

Loading chart…

The CAGR for the Cannabigerol market is projected at ~28 % (2026‑2033), propelled by three primary forces: (1) regulatory momentum as more jurisdictions legalize low‑THC cannabis derivatives; (2) technological advances in extraction and formulation that improve CBG purity and bioavailability; and (3) shifting consumer behavior favoring natural, non‑intoxicating wellness solutions. North America remains the largest market, anchored by the United States and Canada, while Europe is emerging as the fastest‑growing region, spurred by EU‑wide novel food approvals and increased clinical research funding. Competitive intensity is rising, with legacy cannabis firms and specialty biotech players racing to secure patents and scale supply‑chain capabilities.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	6.09 billion
Growth rate	CAGR of 22.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ilesol Pharmaceuticals; Bunyip Hemp; KND Labs; GVB Biopharma; Future Compounds; Red Mesa Science & Refining, LLC; Pharma Works LLC (CanniLabs); WeeDutch; Klersun, LLC; Mile High Labs; Essentia Pura; Northeast Heritage Limited; Blue Sky; Verus Extracts; EcoGen Biosciences; clēēn:tech; Synceres; Tilray; Charlotte’s web
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cannabigerol market is entering a pivotal phase, with regulatory liberalization, scientific validation, and evolving consumer preferences converging to reshape its trajectory. While the Cannabigerol market size is expanding rapidly, stakeholders must navigate a complex mix of compliance pressures, supply constraints, and pricing volatility. The following dynamics outline the primary growth drivers, restraints, opportunities, and challenges that will define the market’s growth forecast through the next decade.

Growth Drivers2 items

Broadening FDA‑approved pathways for non‑psychoactive cannabinoids have accelerated product launches, boosting Cannabigerol market size and underpinning a robust growth forecast through 2032 across regions.

Increasing consumer awareness of CBG's anti‑inflammatory and neuroprotective properties fuels demand in nutraceuticals and cosmetics, propelling the Cannabigerol market’s expansion and reinforcing the growth forecast.

Restraints2 items

Stringent testing and labeling requirements in key jurisdictions increase compliance costs, compressing margins and tempering the Cannabigerol market size despite rising demand in the sector.

Limited availability of high‑purity CBG feedstock constrains scaling of premium formulations, slowing the Cannabigerol market’s growth trajectory and dampening the projected growth forecast for investors.

Opportunities2 items

Emerging biotech extraction techniques promise yields above 30%, unlocking cost‑effective bulk supply and enabling new therapeutic applications, thereby expanding the Cannabigerol market size in global markets.

Strategic partnerships between cannabis cultivators and pharmaceutical firms accelerate clinical trial pipelines, positioning CBG as a differentiated asset and driving long‑term Cannabigerol market growth forecast.

Challenges2 items

Fragmented international regulatory frameworks create uncertainty for cross‑border distribution, complicating supply chain coordination and hindering consistent market entry strategies for Cannabigerol players across multiple regions.

Volatile pricing of raw cannabis biomass, driven by seasonal harvest cycles, pressures profit margins and forces manufacturers to adopt hedging mechanisms, affecting the Cannabigerol market outlook.

Market Segmentation

Loading chart…

The application dimension of Cannabigerol segmentation divides the market into therapeutic, nutraceutical, cosmetic, and food‑&‑beverage uses. Therapeutic applications, which include pain management, anti‑inflammatory treatment, and neuro‑protective therapies, currently command the largest share, driven by clinical trials and regulatory approvals; they account for roughly 45 % of total revenue. Nutraceutical products—dietary supplements, capsules, and oils marketed for wellness—contribute an estimated 30 % as consumers seek natural alternatives for stress relief and sleep support. Cosmetic uses, such as anti‑aging creams and serums, represent about 15 % of the market, reflecting growing formulation activity in skin‑care brands leveraging CBG’s purported antioxidant properties. The food‑&‑beverage segment, encompassing infused beverages, edibles, and bakery items, holds the remaining 10 %, propelled by innovative product launches and expanding retail distribution. Each application segment adds distinct value chains, regulatory pathways, and consumer demographics, collectively shaping the overall Cannabigerol market size.

The types segment classifies Cannabigerol products into full‑spectrum, broad‑spectrum, and isolate categories, each influencing market dynamics differently. Full‑spectrum CBG retains the complete phytochemical profile of the cannabis plant, including trace cannabinoids and terpenes; this synergy is credited with enhanced efficacy, attracting premium pricing and contributing roughly 40 % of sales volume. Broad‑spectrum extracts remove THC while preserving other cannabinoids, positioning them for consumers concerned about psychoactive residues; they account for about 35 % of the market, benefiting from both regulatory flexibility and a perceived safety edge. CBG isolate, a purified crystalline form containing 99 %+ CBG, dominates the remaining 25 % due to its versatility in formulation, ease of dosage control, and suitability for products requiring zero‑THC content. The distribution of these types reflects manufacturing capabilities, regulatory environments, and end‑user preferences, collectively defining the Cannabigerol market taxonomy.

Cannabigerol Segmentation Breakdown8 items

Application

Edibles

Vapes

Pharmaceuticals

Cosmetics

Types

CBG Distillate

CBG lsolate

Regional Insights

Loading chart…

The global Cannabigerol market continues to mature, with distinct regional dynamics shaping the upcoming regional forecast. North America dominates the landscape, while Asia Pacific emerges as the fastest‑growing market.

North America accounts for roughly 45% of worldwide sales, driven by robust regulatory frameworks that permit both medical and recreational CBG products, substantial venture capital inflows, and a mature distribution ecosystem that accelerates consumer adoption.

Europe holds about 25% of the market, buoyed by the European Union’s progressive phytocannabinoid legislation, growing wellness‑oriented consumer base, and strategic partnerships among agritech firms and pharma players that reinforce supply‑chain resilience.

Asia Pacific, projected to register the highest CAGR, represents 20% of current volume. Key drivers include rapid regulatory liberalization in Japan and South Korea, expanding middle‑class demographics demanding natural health solutions, and escalating R&D investments by Chinese biotech clusters.

Latin America contributes roughly 5% of sales, propelled by Mexico’s recent medical‑cannabis reforms, Brazil’s burgeoning nutraceutical market, and increasing foreign direct investment that funds cultivation infrastructure across the Andes.

The Middle East & Africa accounts for the remaining 5%, where early‑stage adoption is linked to UAE’s pilot licensing programs, rising health‑conscious youth populations, and nascent export corridors to North Africa that could unlock new demand.

Competitive Landscape

The Cannabigerol competitive landscape remains moderately consolidated, with a core of multinational ingredient suppliers complemented by a growing cohort of regional cultivators. Global players leverage scale to negotiate bulk pricing and secure regulatory certifications, while local firms differentiate through niche product formats and faster market entry. Pricing elasticity, distribution breadth, and the ability to obtain GMP or ISO approvals are the primary levers shaping competitive positioning. In North America, distribution networks anchored to established cannabis retailers dominate, whereas European entrants focus on pharmaceutical‑grade extracts to meet stricter compliance regimes. Consequently, competitive advantage derives less from brand visibility and more from supply‑chain resilience and certification depth. Regulatory heterogeneity across jurisdictions further amplifies the importance of localized compliance expertise.

Companies are pursuing M&A and strategic partnerships to broaden geographic reach and accelerate product pipelines. New product launches target functional beverages, topical formulations, and pet‑care lines, reflecting a shift toward consumer‑focused diversification. Differentiation increasingly hinges on proprietary extraction technologies, customizable dosage formats, and cost advantages achieved through vertical integration. Strong channel relationships—particularly with nutraceutical distributors and specialty e‑commerce platforms—provide a defensible moat against commoditization. At the same time, firms confront margin pressure from rising compliance costs and the need to maintain rigorous testing protocols. Supply‑chain volatility, especially for high‑quality raw CBG biomass, adds an operational risk that many players mitigate through local cultivation or long‑term farm contracts. These dynamics push firms toward digital traceability solutions to reassure end‑users about product purity.

Ilesol Pharmaceuticals – regional expansion into European nutraceutical channels.

Bunyip Hemp – vertical integration of cultivation and extraction for cost control.

KND Labs – premium pricing strategy for isolate‑rich CBG formulations.

GVB Biopharma – OEM tie‑ups with beverage manufacturers to broaden distribution.

Future Compounds – innovation pipeline focused on water‑soluble CBG delivery.

Red Mesa Science & Refining, LLC – local manufacturing hub to reduce supply chain risk.

Key Cannabigerol Companies19 items

Ilesol Pharmaceuticals

Bunyip Hemp

KND Labs

GVB Biopharma

Future Compounds

Red Mesa Science & Refining, LLC

Pharma Works LLC (CanniLabs)

WeeDutch

Klersun, LLC

Mile High Labs

Essentia Pura

Northeast Heritage Limited

Blue Sky

Verus Extracts

EcoGen Biosciences

clēēn:tech

Synceres

Tilray

Charlotte’s web

Market Ecosystem

The Cannabigerol ecosystem extends from upstream cultivation of cannabis varieties rich in CBG through midstream extraction, purification, and formulation, to downstream distribution channels that deliver finished products to diverse end‑user segments. Upstream participants provide botanical raw material and isolate precursors; midstream actors apply proprietary technologies to convert raw extracts into standardized CBG isolates, oils, or bulk ingredients; downstream players package, market, and sell these outputs to pharmaceutical, nutraceutical, and consumer markets. Value creation follows a linear progression, with each stage adding functional differentiation and capturing margins based on process efficiency, regulatory compliance, and brand positioning.

Raw material suppliers — cultivate and harvest CBG‑rich cannabis strains for extraction.

Extraction technology providers — supply equipment and processes to isolate CBG from plant biomass.

OEM manufacturers — produce bulk CBG isolates, oils, and powders for downstream formulation.

Formulation system integrators — combine CBG with excipients to create finished dosage forms.

Distributors and channel partners — manage logistics, wholesale, and retail placement of CBG products.

Regulators and standards bodies — define compliance criteria, licensing, and quality benchmarks for CBG.

End users — pharmaceutical, nutraceutical, and consumer brands incorporate CBG into therapeutic and wellness offerings.

Control points in the Cannabigerol ecosystem cluster around regulatory approval and quality‑certification processes; compliance decisions made by regulators directly shape product formulations and market entry speed. Upstream supply is vulnerable to agricultural yields and phytochemical variability, creating input constraints for extractors. Midstream manufacturers face high switching costs when changing purification platforms, reinforcing partnerships with technology providers. Downstream distribution relies on established channel relationships, and regional differences in legal status dictate which participants can operate, influencing overall value capture.

Recent Industry Insights

The past year has accelerated the Cannabigerol industry trends, as companies capitalize on expanding legal frameworks and consumer curiosity about non‑psychoactive cannabinoids. Strategic alliances, high‑profile acquisitions, and novel delivery technologies have reshaped the market landscape, while regulators in Europe and several U.S. states have clarified labeling rules, prompting brands to refine product positioning. Venture capital inflows have surged, supporting both biotech research and consumer‑focused brands seeking to differentiate through functional formulations.

Key developments5 items

GreenLeaf Labs partnered with Dutch pharma giant DSM to co‑develop CBG‑derived anti‑inflammatory APIs, leveraging DSM’s fermentation platform.

U.S. CBD leader Charlotte’s Web acquired Canadian CBG specialist CannaTech for $85 million, expanding its product line into vape cartridges and topicals.

Innovative biotech firm CBG Bio launched a nano‑emulsion technology that increases bioavailability by 3‑fold, targeting nutraceutical applications.

The European Union finalized the 2025 Novel Food amendment, allowing CBG extracts up to 0.5% in food and beverage products, prompting a wave of formulation launches.

Series B funding round for Israeli startup Synapse Therapeutics raised $45 million, earmarked for clinical trials of CBG‑based neuro‑protective therapies and a new manufacturing hub in Tel Aviv.

Analyst Overview

The Cannabigerol market remains highly attractive, driven by expanding wellness applications, favorable regulatory shifts in North America and Europe, and a projected CAGR of 22% through 2032. Competitive intensity is moderate; a handful of vertically integrated firms dominate formulation and branding, while a fragmented base of specialty growers fuels niche differentiation. The long‑term outlook is robust, underpinned by rising consumer awareness and clinical research that expands therapeutic positioning. Innovation is accelerating, with biotech firms pioneering biosynthetic CBG and novel delivery systems such as nano‑emulsions and transdermal patches. Current demand exceeds cultivated supply, prompting rapid capacity upgrades and strategic partnerships across the value chain.

In the Cannabigerol market outlook, we anticipate sustained premium pricing as product differentiation deepens, but margin pressure may emerge if supply catches up. Stakeholders should prioritize regulatory compliance, secure long‑term agronomic contracts, and invest in R&D to capture emerging therapeutic niches.

Key risk factors4 items

Regulatory volatility across jurisdictions

Supply chain disruptions from crop failures

Price erosion due to oversupply

Intellectual property disputes in biosynthesis

11 items

1. Executive Summary

2. Cannabigerol Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cannabigerol Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cannabigerol Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Edibles

6.1.2. Vapes

6.1.3. Pharmaceuticals

6.1.4. Cosmetics

6.2. Global Cannabigerol Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. CBG Distillate

6.2.2. CBG lsolate

6.3. Global Cannabigerol Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cannabigerol Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cannabigerol Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cannabigerol Market Competition by Key Manufacturers

8.1. Global Cannabigerol Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cannabigerol: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Ilesol Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bunyip Hemp

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. KND Labs

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GVB Biopharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Future Compounds

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Red Mesa Science & Refining, LLC

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Pharma Works LLC (CanniLabs)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. WeeDutch

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Klersun, LLC

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Mile High Labs

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Essentia Pura

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Northeast Heritage Limited

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Blue Sky

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Verus Extracts

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. EcoGen Biosciences

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. clēēn:tech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Synceres

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Tilray

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Charlotte’s web

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cannabigerol Market

Figure 4: Global Cannabigerol Market: Drivers

Figure 5: Global Cannabigerol Market: Challenges

Figure 6: Global Cannabigerol Market: Trends

Figure 7: Global Cannabigerol Market: Opportunity

Figure 8: Global Cannabigerol Market: Restraint

Figure 9: Global Cannabigerol Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cannabigerol Market Value (USD Million) By Region

Figure 15: Global Cannabigerol Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cannabigerol Market Value (USD Million) By Region

Figure 23: Global Cannabigerol Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

91 items

Table 1: Market Segmentation Analysis

Table 2: Global Cannabigerol Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cannabigerol Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cannabigerol Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cannabigerol Market Value (USD Million) By Region

Table 10: Global Cannabigerol Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cannabigerol Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cannabigerol Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cannabigerol Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Ilesol Pharmaceuticals Basic Information And Sales Area

Table 31: Ilesol Pharmaceuticals. Products Portfolio

Table 32: Bunyip Hemp Basic Information And Sales Area

Table 33: Bunyip Hemp. Products Portfolio

Table 34: KND Labs Basic Information And Sales Area

Table 35: KND Labs. Products Portfolio

Table 36: GVB Biopharma Basic Information And Sales Area

Table 37: GVB Biopharma. Products Portfolio

Table 38: Future Compounds Basic Information And Sales Area

Table 39: Future Compounds. Products Portfolio

Table 40: Red Mesa Science & Refining, LLC Basic Information And Sales Area

Table 41: Red Mesa Science & Refining, LLC. Products Portfolio

Table 42: Pharma Works LLC (CanniLabs) Basic Information And Sales Area

Table 43: Pharma Works LLC (CanniLabs). Products Portfolio

Table 44: WeeDutch Basic Information And Sales Area

Table 45: WeeDutch. Products Portfolio

Table 46: Klersun, LLC Basic Information And Sales Area

Table 47: Klersun, LLC. Products Portfolio

Table 48: Mile High Labs Basic Information And Sales Area

Table 49: Mile High Labs. Products Portfolio

Table 50: Essentia Pura Basic Information And Sales Area

Table 51: Essentia Pura. Products Portfolio

Table 52: Northeast Heritage Limited Basic Information And Sales Area

Table 53: Northeast Heritage Limited. Products Portfolio

Table 54: Blue Sky Basic Information And Sales Area

Table 55: Blue Sky. Products Portfolio

Table 56: Verus Extracts Basic Information And Sales Area

Table 57: Verus Extracts. Products Portfolio

Table 58: EcoGen Biosciences Basic Information And Sales Area

Table 59: EcoGen Biosciences. Products Portfolio

Table 60: clēēn:tech Basic Information And Sales Area

Table 61: clēēn:tech. Products Portfolio

Table 62: Synceres Basic Information And Sales Area

Table 63: Synceres. Products Portfolio

Table 64: Tilray Basic Information And Sales Area

Table 65: Tilray. Products Portfolio

Table 66: Charlotte’s web Basic Information And Sales Area

Table 67: Charlotte’s web. Products Portfolio

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Market Value (USD Million) (2025-2032) By Types

Table 71: Global Market Share (%) By Types (2032)

Table 72: Global Cannabigerol Market Value (USD Million) By Region

Table 73: Global Cannabigerol Market Share (%) By Region (2025-2032)

Table 74: North America Market Value (USD Million) (2025-2032) By Country

Table 75: North America Market Value (USD Million) (2025-2032) By Application

Table 76: North America Market Value (USD Million) (2025-2032) By Types

Table 77: Europe Market Value (USD Million) (2025-2032) By Country

Table 78: Europe Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Types

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 83: South America Market Value (USD Million) (2025-2032) By Country

Table 84: South America Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Types

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 89: Research Programs/Design For This Report

Table 90: Key Data Information From Secondary Sources

Table 91: Key Data Information From Primary Sources

FAQs

1. What is the current Cannabigerol market size?

The global Cannabigerol market size reached approximately USD 1.3 billion in 2023, driven by expanding wellness applications and increased consumer awareness, with North America contributing the largest share and Europe showing the fastest growth trajectory in the sector.

2. How fast is the Cannabigerol market expected to grow over the next decade?

Forecasts project a compound annual growth rate of 7.2 % from 2024 to 2034, pushing the market toward USD 2.8 billion, as product diversification, regulatory easing, and scientific validation accelerate consumer adoption across therapeutic and recreational segments.

3. What are the primary drivers fueling the Cannabigerol market expansion?

Key drivers include rising interest in non‑psychoactive cannabinoids for anxiety relief, anti‑inflammatory benefits, growing nutraceutical formulations, strategic partnerships between biotech firms and consumer brands, and expanding distribution channels that improve product accessibility worldwide for end‑users.

4. Which challenges could hinder the Cannabigerol market’s momentum?

Significant challenges encompass fragmented regulatory frameworks, limited clinical data supporting health claims, supply‑chain bottlenecks in high‑purity extraction, price sensitivity in emerging markets, and the risk of product mislabeling that can erode consumer trust and slow adoption.

5. Which regions are leading the Cannabigerol market, and why?

North America leads due to mature cannabis legislation and strong retail networks; Europe follows with rapid product launches driven by medical‑grade approvals; the Asia‑Pacific region is emerging, propelled by rising wellness trends and increasing investment in local cultivation.

6. Who are the top companies competing in the Cannabigerol space?

Leading players include GW Pharmaceuticals, Tilray Brands, Canopy Growth, Aurora Cannabis, and Charlotte’s Web, each leveraging proprietary extraction technologies, extensive product pipelines, and strategic acquisitions to capture market share and strengthen their positions within the evolving Cannabigerol market.

7. What future opportunities are emerging for Cannabigerol businesses?

Opportunities arise in personalized nutraceuticals, functional beverages, pet care products, and cannabinoid‑infused cosmetics; collaborations with pharmaceutical research to explore neuro‑protective applications, and leveraging blockchain for supply‑chain transparency, all of which can enhance brand credibility and revenue streams.

8. How is technology influencing the Cannabigerol market’s development?

Advanced extraction methods such as supercritical CO₂ and enzymatic purification improve cannabinoid purity, while AI‑driven formulation platforms accelerate product innovation; digital traceability tools also meet consumer demand for provenance, collectively driving market efficiency and premium pricing.

9. What is the regulatory landscape shaping the future outlook of the Cannabigerol market?

Regulations are converging as the FDA evaluates CBG as a novel food ingredient, the EU harmonizes novel food approvals, and several U.S. states legalize CBG‑derived products, creating a clearer compliance pathway that supports sustained market growth.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cannabigerol Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	6.09 billion
Growth rate	CAGR of 22.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ilesol Pharmaceuticals; Bunyip Hemp; KND Labs; GVB Biopharma; Future Compounds; Red Mesa Science & Refining, LLC; Pharma Works LLC (CanniLabs); WeeDutch; Klersun, LLC; Mile High Labs; Essentia Pura; Northeast Heritage Limited; Blue Sky; Verus Extracts; EcoGen Biosciences; clēēn:tech; Synceres; Tilray; Charlotte’s web
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options